How have NTB shares performed in 2024?

12942 (NTB.V)'s stock was trading at C$0.03 at the beginning of the year. Since then, NTB stock has decreased by 16.7% and is now trading at C$0.03. View the best growth stocks for 2024 here .

How were 12942 (NTB.V)'s earnings last quarter?

12942 (NTB.V) (CVE:NTB) posted its quarterly earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million.

Is 12942 (NTB.V) a good dividend stock?

12942 (NTB.V) (CVE:NTB) pays an annual dividend of C$1.52 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of 12942 (NTB.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 12942 (NTB.V) investors own include ACADIA Pharmaceuticals (ACAD) , Adverum Biotechnologies (ADVM) , Aimmune Therapeutics (AIMT) , ANI Pharmaceuticals (ANIP) , AxoGen (AXGN) , Biohaven (BHVN) , bluebird bio (BLUE) , Blueprint Medicines (BPMC) , Calithera Biosciences (CALA) and Codexis (CDXS) .

How do I buy shares of 12942 (NTB.V)?

Shares of NTB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

CVE:NTB

12942 (NTB.V) (NTB) Stock Price, News & Analysis

→ Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad)

Free NTB Stock Alerts

C$0.02

+0.01 (+25.00%)

(As of 05/15/2024 05:24 PM ET)

Compare

Today's Range: C$0.03
▼
C$0.03
50-Day Range: N/A
52-Week Range: C$0.02
▼
C$0.03

Volume: 1,041 shs
Average Volume: 25,915 shs
Market Capitalization: C$448,500.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get 12942 (NTB.V) alerts:

Ad Porter & Company

What’s Really Next for America…

Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.

Click here to stream this controversial exposé now.

About 12942 (NTB.V)

Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company’s products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

NTB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NTB Stock News Headlines

February 9, 2024 | wsj.com

Bank of Butterfield Ltd.

November 23, 2023 | seekingalpha.com

NTB Dividend Yield Grade

October 19, 2023 | time.com

Ntb Coupons

February 19, 2023 | finance.yahoo.com

NYSE U.S. 100 Index (^NY)

See More Headlines

Receive NTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 12942 (NTB.V) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/15/2014
Today: 5/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Finance
Industry: Regional Banks
Sub-Industry: N/A
Current Symbol: CVE:NTB
CUSIP: N/A
CIK: N/A
Web: neptunekrilloil.com
Phone: +1-450-6872262
Fax: N/A
Employees: 1,134
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -18.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.27
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 17,940,000
Free Float: N/A
Market Cap: C$448,500.00
Optionable: Not Optionable
Beta: 1.72

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

John Moretz
Chairman of the Board
James Stuart Hamilton
President, Chief Executive Officer, Director
Mario Paradis
Chief Financial Officer
Michel Timperio
Senior Vice President of Sales - Global Sales
Pierre Lemieux Ph.D.
Chief Operating Officer of Acasti
Jean-Daniel Belanger
Corporate Secretary and Director - Corporate Affairs
Harlan W. Waksal M.D. (Age 61)
Director
Valier Boivin
Independent Director
Ronald Denis
Independent Director
Adrian Taylor Montgomery
Independent Director

Key Competitors

View All Competitors

NTB Stock Analysis - Frequently Asked Questions

How have NTB shares performed in 2024?: 12942 (NTB.V)'s stock was trading at C$0.03 at the beginning of the year. Since then, NTB stock has decreased by 16.7% and is now trading at C$0.03.
View the best growth stocks for 2024 here.
How were 12942 (NTB.V)'s earnings last quarter?: 12942 (NTB.V) (CVE:NTB) posted its quarterly earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million.
Is 12942 (NTB.V) a good dividend stock?: 12942 (NTB.V) (CVE:NTB) pays an annual dividend of C$1.52 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of 12942 (NTB.V) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 12942 (NTB.V) investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).
How do I buy shares of 12942 (NTB.V)?: Shares of NTB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:NTB) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial